{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:55:06Z","timestamp":1783738506035,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008149","name":"Royal College of Pathologists of Australasia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.pathol.2022.11.009","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T18:21:43Z","timestamp":1675534903000},"page":"449-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-8648","authenticated-orcid":false,"given":"Yagiz","family":"Aksoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9212-6927","authenticated-orcid":false,"given":"Angela","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-9629","authenticated-orcid":false,"given":"Mahiar","family":"Mahjoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8974-6092","authenticated-orcid":false,"given":"Amy","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Sioson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-8666","authenticated-orcid":false,"given":"Mahsa S.","family":"Ahadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9447-1967","authenticated-orcid":false,"given":"Anthony J.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9166-6822","authenticated-orcid":false,"given":"Talia L.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2022.11.009_bib1","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pathol.2022.11.009_bib2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a surveillance, epidemiology, and end results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.pathol.2022.11.009_bib3","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.athoracsur.2007.04.076","article-title":"Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma","volume":"84","author":"Rice","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pathol.2022.11.009_bib4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtcvs.2014.10.041","article-title":"Pleurectomy\/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience","volume":"149","author":"Lang-Lazdunski","year":"2015","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pathol.2022.11.009_bib5","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib6","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2017.73.8401","article-title":"Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis","volume":"35","author":"Nelson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtho.2017.08.012","article-title":"National Cancer Database Report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma","volume":"12","author":"Verma","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103639","article-title":"A\u00a0systematic review and meta-analysis of trials assessing PD-1\/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma","volume":"172","author":"Tagliamento","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pathol.2022.11.009_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2022.11.009_bib10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.21037\/tlcr-20-1114","article-title":"Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study","volume":"10","author":"Brcic","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.009_bib11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.pathol.2020.09.018","article-title":"Programmed cell death 1 ligand 1 (PDL1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status","volume":"53","author":"Rrapaj","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2022.11.009_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920962362","article-title":"PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study","volume":"12","author":"Jin","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-019-0177-8","article-title":"Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1","volume":"7","author":"Rouquette","year":"2019","journal-title":"Biomark Res"},{"key":"10.1016\/j.pathol.2022.11.009_bib15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pathol.2022.11.009_bib16","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib17","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib19","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib20","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/1538-7445.AM2019-2673","article-title":"Abstract 2673: association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) \u00b1 ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC)","volume":"79","author":"Lei","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.009_bib21","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1177\/09603271211017324","article-title":"The usefulness of biomarkers in diagnosis of asbestos-induced malignant pleural mesothelioma","volume":"40","author":"Tanr\u0131verdi","year":"2021","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.pathol.2022.11.009_bib22","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/2326-6066.CIR-20-0983","article-title":"TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma","volume":"9","author":"Hodi","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.pathol.2022.11.009_bib23","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1158\/1078-0432.CCR-20-2790","article-title":"Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab\u00a0+\/- ipilimumab in gastric cancer\/gastroesophageal junction cancer","volume":"27","author":"Lei","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.009_bib24","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pathol.2022.11.009_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/his.14106","article-title":"Stromal tumour-infiltrating lymphocytes (TILs) assessed using the ITWG system do not predict overall survival in a cohort of 337 cases of mesothelioma","volume":"76","author":"Fuchs","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2022.11.009_bib26","doi-asserted-by":"crossref","first-page":"8515","DOI":"10.1200\/JCO.2017.35.15_suppl.8515","article-title":"Immune microenvironment in mesothelioma: looking beyond PD-L1","volume":"35","author":"Thapa","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc"},{"key":"10.1016\/j.pathol.2022.11.009_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib29","series-title":"WHO Classification of Tumors Editorial Board. WHO Classification of Tumors: Thoracic Tumors","article-title":"Tumors of the pleura and pericardium","author":"Nicholson","year":"2021"},{"key":"10.1016\/j.pathol.2022.11.009_bib30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/PAS.0000000000001854","article-title":"A\u00a0critical assessment of current grading schemes for diffuse pleural mesothelioma with a proposal for a novel mesothelioma weighted grading scheme (MWGS)","volume":"46","author":"Fuchs","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2022.11.009_bib31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2022.11.009_bib32","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/modpathol.2015.87","article-title":"Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology","volume":"28","author":"Andrici","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.009_bib33","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis","volume":"26","author":"Iasonos","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib34","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3390\/cancers13092186","article-title":"Meta-analysis of survival and development of a prognostic nomogram for malignant pleural mesothelioma treated with systemic chemotherapy","volume":"13","author":"Kotecha","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2022.11.009_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A\u00a0nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.009_bib37","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.009_bib38","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jtho.2018.07.002","article-title":"Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal","volume":"13","author":"Pelosi","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2022.11.009_bib39","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00428-017-2109-z","article-title":"Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies","volume":"470","author":"Habougit","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2022.11.009_bib40","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00268-017-4424-6","article-title":"A\u00a0nomogram to predict prognosis in malignant pleural mesothelioma","volume":"42","author":"Wang","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.pathol.2022.11.009_bib41","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/1759-7714.13063","article-title":"Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the surveillance, epidemiology, and end results database","volume":"10","author":"Zhou","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.pathol.2022.11.009_bib42","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ejca.2009.04.028","article-title":"A\u00a0prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials","volume":"29","author":"Francart","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pathol.2022.11.009_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cllc.2019.08.003","article-title":"Development of a novel prognostic risk classification system for malignant pleural mesothelioma","volume":"21","author":"Doi","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.pathol.2022.11.009_bib44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/bmj.316.7131.611","article-title":"Why do we need randomised controlled trials to assess behavioural interventions?","volume":"316","author":"Stephenson","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.pathol.2022.11.009_bib45","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/jnci\/djr218","article-title":"Randomized phase II trials: a long-term investment with promising returns","volume":"103","author":"Sharma","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523000466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523000466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:29:31Z","timestamp":1758472171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302523000466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0031302523000466"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2022.11.009","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2022.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}